Compass Therapeutics: Promising Pipeline and Strong Financial Outlook Drive Buy Rating

Compass Therapeutics has a promising pipeline and strong financial outlook, leading H.C. Wainwright analyst Joseph Pantginis to maintain a Buy rating with a $24.00 price target. Positive results from the COMPANION-002 study exceeded expectations, and other assets like CTX-8371 and CTX-10726 have shown promising efficacy signals and preclinical data. The company's strong cash runway is expected to last into 2027, supporting ongoing and future developments.